Patents by Inventor Jon Chatterton

Jon Chatterton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS
    Publication number: 20080051361
    Abstract: RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Application
    Filed: August 24, 2007
    Publication date: February 28, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Jon Chatterton, Abbot Clark
  • RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20070281901
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: May 17, 2007
    Publication date: December 6, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: John Yanni, Jon Chatterton, Diane Senchyna, Daniel Gamache, Steven Miller
  • RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
    Publication number: 20070275922
    Abstract: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 29, 2006
    Publication date: November 29, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, David Bingaman
  • RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
    Publication number: 20070155690
    Abstract: RNA interference, is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
    Type: Application
    Filed: December 19, 2006
    Publication date: July 5, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, David Bingaman
  • RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
    Publication number: 20070149473
    Abstract: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: Jon Chatterton, Abbot Clark
  • RNAi-mediated inhibition of Frizzled Related Protein-1 for treatment of glaucoma
    Publication number: 20060223773
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: March 10, 2006
    Publication date: October 5, 2006
    Applicant: Alcon, Inc.
    Inventors: Abbot Clark, Wan-Heng Wang, Loretta McNatt, Jon Chatterton
  • RNAi-mediated inhibition of ocular targets
    Publication number: 20060172965
    Abstract: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ?1- and ?2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 3, 2006
    Applicant: Alcon, Inc.
    Inventors: Allan Shepard, Jon Chatterton, Abbot Clark, Martin Wax
  • RNAi-mediated inhibition of ocular hypertension targets
    Publication number: 20060172963
    Abstract: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; ?1- and ?2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 3, 2006
    Applicant: Alcon, Inc.
    Inventors: Allan Shepard, Jon Chatterton, Abbot Clark
  • siRNA libraries optimized for predetermined protein families
    Publication number: 20050026172
    Abstract: Libraries for generating small interfering RNA (siRNA) are provided where the members of the library are optimized to inhibit the expression of genes that encode a predetermined family of proteins. The members of the library target at least mRNA encoding all members of the family of proteins. Methods for generating siRNA libraries of the present invention are also provided.
    Type: Application
    Filed: February 10, 2004
    Publication date: February 3, 2005
    Applicant: Immusol, Inc.
    Inventors: Henry Li, Jon Chatterton, Wufang Fan, Ning Ke, Flossie Wong-Staal